Adviser platform tech provider FNZ up for sale - reports

Worth 'up to £2bn'

clock • 1 min read

FNZ, technology provider to a number of adviser platforms, is drawing up plans for a sale that could be worth up to £2bn, according to reports.

According to Sky News, the business is in the process of appointing advisers for a sale of a majority stake in the company, which provides technology for Standard Life, Aviva, Old Mutual Wealth and Embark adviser platforms. It also provides technology to other financial groups, such as Barclays and HSBC. "City sources" said FNZ could be valued anywhere between £1bn and £2bn and the sale process was expected to kick off before the end of the year. Why the sudden craze for platform floats? General Atlantic and HIG Europe both currently own one-third of the company and are expected...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot